Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors
- 1 October 1998
- journal article
- Published by Elsevier in Chemistry & Biology
- Vol. 5 (10) , 597-608
- https://doi.org/10.1016/s1074-5521(98)90117-x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2′ groupsBioorganic & Medicinal Chemistry Letters, 1998
- Recent developments in HIV protease inhibitor researchExpert Opinion on Therapeutic Patents, 1997
- Potent cyclic urea HIV protease inhibitors with benzofused heterocycles as P2/P2′ groupsBioorganic & Medicinal Chemistry Letters, 1996
- Stereoselective Synthesis of HIV-1 Protease Inhibitor, DMP 323The Journal of Organic Chemistry, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Limited Sequence Diversity of the HIV Type 1 Protease Gene from Clinical Isolates andin VitroSusceptibility to HIV Protease InhibitorsAIDS Research and Human Retroviruses, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease InhibitorsScience, 1994
- Protein Binding of PropisomideJournal of Pharmaceutical Sciences, 1985